Table 1.
Characteristics of study population
| All patients N = 166 | TDF treatment N = 119 | Treatment-naïve = 47 | P value | |
|---|---|---|---|---|
| Female, No. (%) | 112 (67.5) | 86 (72.3) | 26 (55.3) | 0.044 |
| Age (years), median (Q1, Q3) | 42 (35, 49) | 44 (36, 50) | 37 (31, 46) | 0.006 |
| (min.–max.) | (18–70) | (18–69) | (20–70) | |
| Serum creatinine (mg/dL), median (Q1, Q3) | 1.2 (1, 1.4) | 1.1 (0.9, 1.3) | 1.2 (1, 1.7) | 0.009 |
| eGFR (mL/min), mean (SD) | 76.3 (26.8) | 78.2 (26.0) | 71.4 (29.6) | 0.143 |
| eGFR < 60/mL/min, No. (%) | 48 (28.9) | 29 (24.4) | 19 (40.4) | 0.041 |
| Current CD4-count/µL mean (SD) | 387 (259) | 460 (255) | 204 (158) | < 0.001 |
| WHO status, No. (%) | 162 (100) | 116 (100) | 46 (100) | 0.007 |
| I | 39 (24.1) | 21 (18.1) | 18 (39.1) | |
| II | 30 (18.5) | 27 (23.2) | 3 (6.5) | |
| III | 76 (46.9) | 54 (46.6) | 22 (47.9) | |
| IV | 17 (10.5) | 14 (12.1) | 3 (6.5) | |
| Proteinuria, No. (%) | 55 (35.4) | 31 (26.1) | 24 (52.2) | 0.003 |
| Erythrocyturia (> 5/μL), No. (%) | 48 (29.3) | 32 (27.1) | 16 (34.8) | 0.310 |
| Leukocyturia, No. (%) | 54 (32.9) | 41 (34.5) | 13 (28.9) | 0.578 |
| Glucosuria, No. (%) | 3 (1.8) | 3 (2.5) | – | 0.561 |
| Renal echogenicity, No. (%) | 0.376 | |||
| Normal | 105 (63.3) | 73 (61.3) | 32 (68.1) | |
| G1 | 54 (32.5) | 42 (35.3) | 12 (25.5) | |
| G2 | 7 (4.2) | 4 (3.4) | 2 (4.3) | |
| Kidney size (cm), mean (SD) | 10.6 (1.1) | 10.3 (1.0) | 11.1 (1.2) | < 0.001 |
| mean arterial blood pressure (mm of Hg), median (Q1, Q3) | 91.7 (83.3, 100) | 93.3 (84.6, 103) | 86.7 (83.3, 93.3) | 0.002 |
| arterial hypertension (> 140/90), No. (%) | 47 (29.6) | 39 (34.2) | 8 (17.8) | 0.053 |
| fasting blood sugar (mg/dL), median (Q1, Q3) | 84 (73, 96) | 84 (73, 94) | 85 (69.5, 99.3) | 0.955 |
| TBC, No. (%) | 8 (4.8) | 1 (0.8) | 7 (14.9) | 0.001 |
eGFR = estimated glomerular filtration rate (by CKD EPI formula); TBC = tuberculosis. P value comparing patients on TDF treatment with treatment-naïve patients.